Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

G Medical Innovations Holdings Ltd. Scheduled to Launch Covid-19 Testing Centers in California as Part of New Direct-to-Consumer Initiative

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced plans to open as many as 25 Covid-19 testing centers in California in Q1, 2022. Known for its groundbreaking technology, remote patient monitoring devices and services utilized by hospitals and cardiologists across the country, GMedical’s innovative Prizma monitoring device will be offered direct-to-consumer for the first time at these testing locations, as part of an aggressive company direct-to-consumer strategy. Prizma is a user-friendly cell phone-sized device that can help monitor user’s vital signs, providing to-the-minute readings for ECG, temperature, oxygen saturation, heart rate, stress levels and blood pressure, help track body weight and glucose levels. Data is presented directly to the user and the designated care provider. G Medical’s remote patient monitoring center can alert users to readings that may be a cause for concern. Prizma can also be prescribed by physicians to patients with cardiac or respiratory disease, diabetes and other health issues. With the explosive growth in demand for Covid testing across the country, G Medical expects its new California locations to boost Prizma sales. “By offering Prizma at our Covid19 testing sites we are empowering consumers to measure and monitor their vital signs post testing, in the comfort of their own home,” said G Medical CEO Dr. Yacov Geva. “This unique opportunity to introduce our Prizma device to customers face-to-face at the point of sale is an important step forward in our company’s direct-to-consumer initiative.” Prominent Santa Monica physician Dr. Rand McClain agrees. “G Medical’s Prizma vital sign monitoring device can provide ‘next level’ of care, by empowering patients to measure and record their vital signs daily.” Telehealth services and the use of remote patient monitoring more than doubled from 2018 to 2020, and that growth continues, according to a recent report by the American Medical Association (AMA). Within this industry, G Medical Innovations is well positioned as a next-generation mobile health (mHealth) and e-health company that develops and markets its clinical and consumer medical-grade health monitoring solutions, and offers end-to-end support for e-health projects. With extensive experience in the field of digital health and project management, GMedical Innovations is committed to raising the global level of healthcare by empowering caregivers and patients to better monitor, manage and improve clinical and personal health outcomes. About G Medical Innovations Holdings Ltd. G Medical Innovations Holdings Ltd. Is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses plans to open as many as 25 Covid-19 testing centers in California in Q1, 2022, its direct-to-consumer strategy and the benefits and advantages of its Prizma medical device. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, G Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical is not responsible for the contents of third-party websites. Contact Details G Medical Innovations Holdings Ltd. G Medical Service +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

December 01, 2021 07:15 AM Eastern Standard Time

EXCHANGE LISTING, LLC ASSISTS ADVANCED HUMAN IMAGING TO LAUNCH ITS AMERICAN DEPOSITARY RECEIPTS ON NASDAQ

Exchange Listing

Exchange Listing, LLC announced that its client, Advanced Human Imaging (Advanced Human Imaging or “The Company”), a rapidly growing medical technology company has commenced its listing on the Nasdaq Capital Market (“Nasdaq”) with American Depositary Receipts (“ADR’s”). Based in Perth, Australia, American Human Imaging, is a cutting-edge mHealth technology enterprise that uses artificial intelligence to make human scanning possible from a smartphone. The Company’s ADRs commenced trading on NASDAQ on November 19th, 2021 under the ticker symbol, (NASDAQ: AHI). The pricing of the Company’s U.S. initial public offering of 1,000,000 units is at a price to the public of US$10.50 per unit. Each unit issued in the offering consisted of two American Depositary Shares ("ADSs") and one warrant to purchase one ADS. Each ADS offered represents 7 ordinary shares of AHI. The warrants are exercisable immediately, and expires three years from the date of issuance and have an exercise price of US$5.52 per ADS. The ADSs and warrants are immediately separable and were issued separately. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately US$10.5 million. The Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ADSs and/or up to an additional 150,000 warrants to purchase up to 150,000 ADSs at the public offering price, less underwriting discounts, and commissions. “ Exchange Listing was instrumental in our achieving a listing on Nasdaq, the world's most prestigious platform for emerging growth companies,” said Vlado Bosanac. “Their guidance and knowledge was immensely valuable throughout the early stages of this complex process. This important step for AHI will allow us to increase liquidity and gain exposure for the Company with institutional and retail investors in the United States.” “Clearly, Advanced Human Imaging has transformed a smartphone into a health risk assessment tool,” said Peter Goldstein, CEO, Exchange Listing. “ The Company’s revolutionary technology can be used to assess and capture chronic disease risks or more simply track fitness goals in under one minute. There’s no doubt about the product's innovation and tremendous U.S. market potential.” Exchange Listing provides companies with cost-effective and efficient direct access to one-stop solutions in the strategic planning and implementation of listing and up-listing on senior exchanges such as the Nasdaq or NYSE. Focusing on company-specific structuring to meet listing requirements, Exchange Listing serves as the primary point of contact with the exchange, investment bankers and lawyers throughout the listing process. With extensive experience in investment banking, securities law, corporate governance and business management, Exchange Listing and its strategic partners facilitate clients' listing and capital markets objectives. About Exchange Listing Exchange Listing provides growth companies with direct access to a one-stop solution in the strategic planning and implementation of listing on a senior exchange such as NASDAQ or NYSE in a cost effective and efficient process. We assist clients in going public whether through an initial public offering, listing from another marketplace, merger or direct offering. We serve as the primary point of contact with the exchange, investment bankers, lawyers and other service providers. Our founders, strategic partners and advisors are entrepreneurs with backgrounds in investment banking, securities law, corporate governance and business management and have served as officers and directors of public and private companies. We pride ourselves in taking a hands-on role with our clients throughout the listing process. For more information, please visit: www.exchangelistingllc.com or contact info@exchangelistingllc.com. About Advanced Human Imaging: AHI has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions in conjunction with known health risk indicators using only a smartphone both privately and accurately. Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes, or simply wanting to be correctly sized for a garment when shopping online. The AHI technology delivers this seamlessly, privately, and cost-effectively in under one minute. AHI has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process the images and assessments on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivalled in the industry. AHI simplifies the collection of measurements and removes the human error present in traditional methods. Contact Details WantLeverage Communications Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://exchangelistingllc.com/

November 29, 2021 08:07 AM Eastern Standard Time

100 Houstonians in Harris and Ft. Bend Counties Awarded a Total of $1 Million Through Comcast RISE, National Initiative to Support Small Business Owners

Comcast Houston

Comcast today announced the 100 recipients of the Comcast Rise Investment Fund grants. Each small business will receive a one-time $10,000 grant from the fund. More than 100 businesses in the area will also receive technology and marketing resources. The recipients are among nearly 6,700 entrepreneurs nationwide who have been selected through the Comcast RISE program, which provides marketing, technology, and capital support to small business owners. “We are proud of all of our small businesses, the impact they have in Fort Bend County is invaluable. Many of our business owners, particularly our minority owned businesses, have faced unprecedented challenges over the past year due to the COVID-19 pandemic, and require a wide range of support to help their businesses survive,” stated Fort Bend County Judge KP George. “The Comcast Rise Investment Fund Grant provides these business owners with the critical financial lifeline and the resources needed so they can sustain and grow their businesses.” Through Comcast RISE, the company also announced it is on track to support 13,000 small businesses by the end of the year with marketing or technology support such as a TV campaign, production of a TV commercial or consulting services from Effectv, the advertising sales division of Comcast Cable, or computer equipment, internet, voice or cybersecurity services from Comcast Business. “Since we launched Comcast RISE a year ago, we have assisted more than 200 small businesses throughout the Houston area with either marketing, technology, or monetary grants. This round of Comcast RISE grants will provide even more small business owners of color with the resources and tools they need to thrive,” said Ralph Martinez, senior vice president for Comcast’s Houston region. “We look forward to empowering their success.” To further build on the program’s success and provide support to even more small businesses, Comcast also announced today a major expansion to eligibility, enabling all women-owned small businesses nationwide to apply. This expansion recognizes and seeks to help address the persistent inequities women continue to face in accessing the resources and funding that are critical to success. Comcast RISE and the Comcast RISE Investment Fund, initially launched as a response to help small businesses owners of color hardest hit by the economic impacts of the COVID-19 pandemic, continue to focus on uplifting small businesses, ensuring they continue to prosper in an ever-shifting post-pandemic economy. “As we continue to rebuild and emerge from the effects of the pandemic, small businesses will continue to be the backbone of our economy – and we must take every opportunity to help them thrive,” said Dave Watson, President and CEO, Comcast Cable. “Looking forward, this expansion will enable Comcast RISE to further empower and strengthen even more small businesses that are the heart of our local communities across the country.” In the year since its inception, Comcast RISE has awarded more than $11 million in grants and $50 million in in-kind support for marketing and technology services, impacting more than 6,700 entrepreneurs of color in 432 cities across 34 states. By the end of 2022, 13,000 businesses across the country are expected to benefit from the Comcast RISE initiative, either through the grant program or from the resources provided through Effectv and Comcast Business. In addition to the financial and business support services provided, a key part of the program is ensuring the long-term sustainability of businesses. To help address this, Comcast invests in and partners with organizations such as Ureeka to provide ongoing mentorship and resources to help small businesses succeed over the long-term. Comcast RISE, which stands for Representation, Investment, Strength, and Empowerment, is part of Project UP, Comcast’s comprehensive initiative to advance digital equity and help provide underrepresented small business owners with access to the digital tools and funding they need to thrive. Over the next 10 years, Comcast has committed $1 billion to programs and partnerships that will reach an estimated 50 million people with the skills, opportunities, and resources they need to succeed in an increasingly digital world. The program will continue to be open to racially and ethnically diverse small business owners and the expanded Comcast RISE eligibility to all women-owned businesses will be effective on January 16, 2022. More information and the applications to apply for either the grant program or marketing and technology services are available at www.ComcastRISE.com. To help drive outreach and awareness about Comcast RISE and provide additional support, training and mentorship, Comcast has also awarded $50,000 in grants to local community partners – Houston Hispanic Chamber, Houston Black Chamber, Empresarios Latinos Foundation, Houston LGBT Chamber, Asian Chamber of Commerce, Greater Houston Women’s Foundation and East End Chamber of Commerce. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company that connects people to moments that matter. We are principally focused on broadband, aggregation, and streaming with 57 million customer relationships across the United States and Europe. We deliver broadband, wireless, and video through our Xfinity, Comcast Business, and Sky brands; create, distribute, and stream leading entertainment, sports, and news through Universal Filmed Entertainment Group, Universal Studio Group, Sky Studios, the NBC and Telemundo broadcast networks, multiple cable networks, Peacock, NBCUniversal News Group, NBC Sports, Sky News, and Sky Sports; and provide memorable experiences at Universal Parks and Resorts in the United States and Asia. Visit www.comcastcorporation.com for more information. About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About Effectv Effectv, the advertising sales division of Comcast Cable, helps local, regional and national advertisers use the best of digital with the power of TV to grow their business. It provides multi-screen marketing solutions to make advertising campaigns more effective and easier to execute. Headquartered in New York with offices throughout the country, Effectv has a presence in 66 markets with nearly 35 million owned and represented subscribers. For more information, visit www.effectv.com. Contact Details Comcast Foti Kallergis +1 832-986-0196 Foti_Kallergis@comcast.com Comcast Misha McClure +1 832-547-6783 Misha_McClure@cable.comcast.com Company Website https://houston.comcast.com/

November 23, 2021 09:31 AM Central Standard Time

ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY

Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that its COVID-19 trial (“C001”) for OT-101 has successfully met its safety and efficacy endpoints. OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β by OT-101 is expected to impact both cancer and COVID. By targeting the host protein, OT-101 is expected to work against multiple respiratory viruses, including related emerging variants, unlike traditional antiviral drugs and vaccines. On October 18, Data lock and Study Data and Analysis Data Models (SDTMs & ADaMS Databases) were generated for a Phase 2 C001 Covid Study: “A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT-101 in Hospitalized COVID-19 Subjects”. The trial compares OT-101 + Standard of Care (“SOC”) versus Placebo + SOC (N= 32 patients, at 2:1 randomization ratio). SOC includes dexamethasone, the only drug known to improve outcomes in severe cases of COVID-19. The top line data is: Safety endpoints met. OT-101 as a TGF-β inhibitor was safe to administer to COVID-19 patients including severe/critical COVID-19 patients. Efficacy signals were obtained. End of treatment (Day 7) mortality for the entire study population was 4.5% OT-101 versus 20% for placebo. Incidence of >96% viral load knockdown on End of Treatment (Day 7) was 89% for OT-101 versus 67% for placebo. Overall survival improved 3X for critical COVID-19 patients (4 days for placebo versus 14 days for OT-101, p < 0.0166). “It is gratifying that the TGF-β concept that we put forward has now been validated,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The data form the basis for further development of OT-101 as a viable treatment for severe respiratory viral infections, including flu and COVID-19. We thank the patients and investigators involved, especially Dr. Carbajal of Calle Mariscal Sucre, Chancay, Huaral, Lima, Peru, who drove the study to its conclusion.” “The resulting data clearly suggest a favorable clinical response to OT-101 in the treatment of patients with COVID-19,” noted Dr. Anthony Maida, Chief Clinical Officer – Translational Medicine. “Additionally, we were able to demonstrate that there is no evidence of delivering OT-101 and any effect relating to cytokine release syndrome.” Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-beta therapeutics for oncology and virology. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2021 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-beta immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-beta RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019. For more information, please visit www.oncotelic.com. Contact Details Oncotelic Therapeutics Inc Amit Shah ashah@onoctelic.com Company Website https://www.oncotelic.com

November 23, 2021 07:00 AM Eastern Standard Time

Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug Development

Variational AI

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today announced that it has raised $US3.5 million ($CDN4.3 million) in seed funding. The investment round was led by Flying Fish Ventures, Alliance of Angels and A&E Investments, with participation from Lip-Bu Tan and Amarjit Gill, Silicon Valley entrepreneurs, investors and advisors. Variational AI’s Enki algorithm learns from a training set of molecules screened against drug targets from both experimental and computational sources and then generates novel molecular structures with multiple pre-defined parameters/properties optimized to avoid common causes of drug attrition. This optimization is performed in parallel and can deliver results in months versus years and requires significantly less data than competing AI offerings. “The pandemic has demonstrated the importance of accelerating drug discovery and reducing the cost and risk to developing therapeutics,” said Frank Chang managing partner, Flying Fish. “We are thrilled to invest in Variational AI’s machine learning approach to discovering new molecules, which has the potential to dramatically impact the biopharma industry.” The seed funding will enable Variational AI to accelerate existing discovery programs for COVID-19, cancer and other disease areas. The company will also utilize the new capital to hire additional leaders in medicinal chemistry, cheminformatics, and machine learning, and recruit a Scientific Advisory Board. “The Variational AI team is excited to welcome our investors in sharing our vision for redefining the economics of drug development,” said Handol Kim, co-founder and CEO, Variational AI. “We look forward to accelerating our current programs and identifying new drug targets that Enki is uniquely suited to tackle to rapidly address unmet medical needs.” About Variational AI Variational AI uses state-of-the-art machine learning in a data-efficient method to rapidly generate novel and diverse compounds that are optimized for multiple properties to avoid the most common causes of drug attrition and increase clinical probability of success. Variational AI works with leading biopharmaceutical partners and is developing its own internal pipeline. To learn more, visit https://variational.ai. Contact Details Sage Morander +1 401-490-9700 variationalai@svmpr.com Company Website https://variational.ai/

November 17, 2021 10:15 AM Eastern Standard Time

ATAP ACTION NETWORK PHYSICIANS & PATIENT ADVOCATES MEET WITH CONGRESSIONAL OFFICES

Alliance for Transparent & Affordable Prescriptions

Today, physician and patient advocates on behalf of the Alliance for Transparent and Affordable Prescriptions (ATAP) Action Network (AN) will meet virtually with congressional lawmakers’ offices as part of its 2021 Capitol Hill Day. In these meetings, ATAP member organizations are advocating for lowering prescription drug prices for their patients by bringing accountability to the pharmacy benefit manager (PBM) industry. ATAP is an active advocate for patients in federal and state battles to amplify the voices of patients and physicians – especially as it relates to exposing PBM abuses and the impact on access to therapies (medications) needed for the treatment of patients. In the meetings today, ATAP AN will speak to congressional offices about three pieces of legislation, including: the PBM Accountability Study Act (H.R. 1829/S. 298), the Drug Price Transparency Act (S. 1523), and the Prescription Pricing for the People Act (S. 1388). “We are proud to bring policymakers the voices of patients and providers, two groups grossly underrepresented in the drug pricing debate’” said Dr. Robert Levin, the President of ATAP. “These voices from our members, combined with supporting advocacy organizations, and individuals fearing drug cost affordability, will surely inspire national leaders to take action to fix problems created by the PBM industry.” ATAP AN will meet with congressional member offices from Florida, Wisconsin, New York, Virginia, North Carolina, Missouri, Maryland, and California. Michael Schweitz, President of ATAP Action Network and Member of the Florida Society of Rheumatology, stated, “Officials in Washington understand that our members, those on the front lines of medical care, offer a valuable perspective. We see the struggles and confusion that patients are put through by this completely unnecessary middleman industry. We appreciate to opportunity to share these experiences and help more legislators see the light – and shine it on the PBMs.” Several ATAP member organizations are participating in meetings including, the American College of Rheumatology, the Coalition of State Rheumatology Organizations, Lupus and Allied Diseases Association, Inc., and many others. Kathleen A. Arntsen President & CEO of Lupus and Allied Diseases Association, (an ATAP member organization) stated, "As a patient-led organization representing those facing serious health conditions, we have direct experience with the frustration in struggling to access affordable and appropriate treatments due to PBM interference. We are thrilled to have the opportunity to share this information with elected officials and are hopeful that they will stand with patients and support fair drug pricing legislation that holds the PBM industry accountable." “PBMs generate significant profits while patients struggle to afford the cost of care,” said Steven Newmark, Director of Policy at the Global Healthy Living Foundation (an ATAP member organization). “We will show elected officials and policymakers what is really happening in exam rooms, and the stress patients experience due to PBM interference. There is a better way.” Updates from the meetings will be shared at https://atapadvocates.com/ and on Twitter with the hashtag, #ATAPHillDay21. About ATAP ATAP was created in 2017 with a mission to address prescription drugs costs and patient access to affordable treatment by regulating PBM practices and reforming the drug industry through educational outreach and grassroots advocacy initiatives at both the state and federal levels. Driven by the reality that many patients struggle to afford their medications, the physician and patient advocacy organizations joined to shine a light on the abusive practices of PBMs. ### To schedule an interview with an ATAP spokesperson please contact Dan Rene of kglobal at 202-329-8357. Please visit http://www.atapadvocates.com ATAP's mission is to address prescription drugs costs and patient access to affordable treatment by regulating PBM practices and reforming the drug industry through educational outreach and grassroots advocacy initiatives at both the state and federal level. Contact Details Dan Rene +1 202-329-8357 daniel.rene@kglobal.com Company Website http://www.atapadvocates.com

November 16, 2021 10:58 AM Eastern Standard Time

AppYea takes steps for Future Growth

Appyea

Provides the following letter to its shareholders from its Chairman Boris Molchadsky: "I am pleased with the progress AppYea/SleepX has been making this year. As part of the long terms objective, AppYea Inc. (OTCPINK: APYP) took the initial step to advance the prospects of the Company. As disclosed in our quarterly report yesterday to the OTC for the recently completed fiscal quarter, the reverse stock split, for which we are awaiting FINRA approval, is a proactive measure that we believe will better position us for success, and ultimately generate value for all of the Company’s stockholders. The ultimate aim is to raise our stock’s visibility within the investment community by improving long-term liquidity and creating a trading environment attractive to institutional investors in the hopes of broadening our shareholders. We are confident of the prospects of the anticipated commercialization of the SleepX DreamIT X3 in 2022". Mr. Molchadsky continued: “In conjunction with the corporate actions, AppYea has secured funding sources who we believe will asist the Company to restructure prior highly dilutive debt and providing the necessary capital to enable the Company to move forward on several fronts, including: 1. Closing of the merger between AppYea and SleepX—we are awaiting the required necessary regulatory approvals. 2. Completion of development and commencement of manufacturing the first product for snoring treatment. SleepX intends to start a pilot in December with a leading hardware manufacturer after withstanding the Company's endurance tests. 3. Preparation for starting clinical trials of the product for the treatment of Sleep Apnea. 4. Locating and acquiring synergetic technologies and broadening products variety in the sleeping and respiration field. Looking ahead, the primary focus of the Company is to ensure the long-term success of the Company by acting in the best interest of all of our shareholders. Thank you for your continued support and patience”. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

November 16, 2021 09:09 AM Eastern Standard Time

Image

New Options to Treat Alcohol Use Disorder

YourUpdateTV

Nearly 15 million Americans have alcohol use disorder and 75 million engaged in binge drinking or heavy alcohol use in the month before a survey conducted by the National Institute of Alcohol Abuse and Alcoholism. This problem has not been solved…yet. Hope for a solution is one of the big stories coming out of the Wonderland Conference, the largest psychedelic business event, ever. YourUpdateTV spoke with Awakn Life Sciences CEO, Anthony Tennyson who discussed the problem. “Alcohol addiction is a chronic disease effecting many millions of Americans each year. The success rates for treatments are typically quite low though. Three out of four people are back drinking alcohol within 12 months of seeking treatment. There is, however, a new hope. Psychedelic assisted therapy has been proven to be more effective at treating alcohol addiction than any other currently available treatment.” Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, recently announced that the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) psychotherapy intervention study, which was the first controlled study in the world to investigate ketamine-assisted psychotherapy, will be published in the American Journal of Psychiatry later this year. Professor David Nutt, former Clinical Director of the US National Institute of Alcohol Abuse and Alcoholism and currently Clinical Director at Awakn commented. The approach we’re taking is to use new medicines to disrupt the brains processes of addiction to allow people to escape from the repetitive cravings and which tie them to the alcohol and and also with therapy to help them plot a new path in their lives. About Awakn Life Sciences Corp.: Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver this evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 15, 2021 07:11 PM Eastern Standard Time

Video

POCONO ORGANICS INTRODUCES NEW CBD GOURMET GUM DROP LINE

Pocono Organics

Pocono Organics’ CBD product line continues to grow as the woman-owned company introduced two new flavorful gourmet attractions, Lemon Chamomile and Vanilla Lavender CBD Gum Drops today. From hemp growing in the nutrient rich fields; transformed into new life as gourmet gum drops formulated by their scientists and Chopped Champion Chef, the pair puts Pocono Organics on the map with the number one form of CBD consumption. “Growing the first and only Regenerative Organic Certified (ROC) hemp in the world and being the largest ROC farm in the U.S.; we tend to set the bar kind of high for our CBD team to excel in creating a premium, wellness product line dedicated to providing convenience and taste-appeal,” smiles Ashley Walsh, Pocono Organics Founder/President. Formulated in-house, each Gourmet Gum Drop tin includes 25 servings and fits right in with Pocono Organics’ small batch, artisanal CBD product line featuring Bath Bombs, Nano-Particle Tincture, Hemp Extract Tincture, Creams, Salve Sticks, and Lip Balms. There’s even a pet-friendly Furry Friends Tincture! Learn more Pocono Organics CBD facts and focus on the future, including its water-soluble nano-particle technology, at PoconoOrganics.com/cbd. Pocono Organics – Inspiring People. Healing the Earth. 1015 Long Pond Road, Long Pond, PA – PoconoOrganics.com About Pocono Organics Pocono Organics is a health and wellness organization with a mission to inspire people and heal the earth. The Global Center for Research, Education, and Innovation grows the world’s first and only Regenerative Organic Certified (ROC) hemp and is one of the largest ROC farms in North America. Located in Long Pond, Pennsylvania, Pocono Organics has more than 380 acres of farmland and, at full build out, will have 120,000 square feet of greenhouse. Pocono Organics has a strategic partnership with Rodale Institute, the global leaders in Regenerative Organic Agriculture science and research and is their largest research satellite facility. Awarded the 2019 Environmental Innovator of the Year by the Green Sports Alliance, sustainability is a hallmark of Pocono Organics. The farm draws power from a 3MW, 25-acre solar farm and reclaims rainwater from 70,000 square feet of roofs for irrigation. Pocono Organics also serves the local community through its Clean Food, Dirty Hands school education program and veterans in transition through a Veteran Farmer Training Program. In addition, the property includes an organic farmer’s market and café featuring a Chopped Champion Chef, and with a 56-room adjoining hotel, is an agritourism destination, and host location for annual festivals. Please visit www.PoconoOrganics.com to learn more about Pocono Organics’ mission and work. Contact Details Pocono Organics Jeanine Hofbauer, Corporate Director of Marketing & Communications +1 570-517-1792 Jeanine@PoconoOrganics.com Company Website https://www.poconoorganics.com/

November 15, 2021 02:00 PM Eastern Standard Time

Image

1 ... 188 189 190 191 192 ... 235